Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hepion Pharmaceuticals Inc HEPA

Healthcare
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases. The Company is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease. It is developing rencofilstat as its lead molecule. Rencofilstat is a compound that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulate protein folding, in addition to other activities. It has developed and maintains an artificial intelligence deep machine learning (AI/ML) platform designed to understand disease processes and identify patients that are rencofilstat responders. In addition, its AI/ML can be used to further NASH and HCC clinical development programs.


NDAQ:HEPA - Post by User

Hepion Pharmaceuticals Inc
<< Previous
 Bullboard Posts
User Avatar Image
(267)
•••
Post by whytestockson Apr 22, 2024 5:17pm
51 Views
Post# 36002143

Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals S

Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals S
BREAKING NEWS: $HEPA Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday? | BenzingaFriday,&nbsp;Hepion Pharmaceuticals Inc.&nbsp;(NASDAQ:HEPA) said it has begun winding down activities in its ASCEND-NASH Trial while continuing to ...HEPA - Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday? | Benzinga

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities